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Background: In this study, primary rat alveolar epithelial cell monolayers (RAECM) were 
used to investigate transalveolar epithelial quantum dot trafficking rates and underlying trans-
port mechanisms.
Methods: Trafficking rates of quantum dots (PEGylated CdSe/ZnS, core size 5.3 nm, hydro-
dynamic size 25 nm) in the apical-to-basolateral direction across RAECM were determined. 
Changes in bioelectric properties (ie, transmonolayer resistance and equivalent active ion trans-
port rate) of RAECM in the presence or absence of quantum dots were measured. Involvement 
of endocytic pathways in quantum dot trafficking across RAECM was assessed using specific 
inhibitors (eg, methyl-β-cyclodextrin, chlorpromazine, and dynasore for caveolin-, clathrin-, and 
dynamin-mediated endocytosis, respectively). The effects of lowering tight junctional resistance 
on quantum dot trafficking were determined by depleting Ca2+ in apical and basolateral bathing 
fluids of RAECM using 2 mM EGTA. Effects of temperature on quantum dot trafficking were 
studied by lowering temperature from 37°C to 4°C.
Results: Apical exposure of RAECM to quantum dots did not elicit changes in transmonolayer 
resistance or ion transport rate for up to 24 hours; quantum dot trafficking rates were not sur-
face charge-dependent; methyl-β-cyclodextrin, chlorpromazine, and dynasore did not decrease 
quantum dot trafficking rates; lowering of temperature decreased transmonolayer resistance by 
approximately 90% with a concomitant increase in quantum dot trafficking by about 80%; and 
24 hours of treatment of RAECM with EGTA decreased transmonolayer resistance by about 
95%, with increased quantum dot trafficking of up to approximately 130%.
Conclusion: These data indicate that quantum dots do not injure RAECM and that quantum 
dot trafficking does not appear to take place via endocytic pathways involving caveolin,   clathrin, 
or dynamin. We conclude that quantum dot translocation across RAECM takes place via both 
transcellular and paracellular pathways and, based on comparison with our prior studies, inter-
actions of nanoparticles with RAECM are strongly dependent on nanoparticle composition 
and surface properties.
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Introduction
Nanoparticles (with at least one dimension #100 nm) offer novel opportunities for 
biomedical applications, yet their mechanisms of interaction with biological cells, 
tissues, and organs (including the lung) have not been well defined. Recent reports 
have highlighted the need for systematic investigation of unknown, but potentially 
harmful, effects of nanomaterials in order to permit safer design and application 
in biomedicine.1–4 Ultrafine ambient particles (diameter ,100 nm) overlap in size 
with engineered nanomaterials. Systematic studies of toxicity/trafficking of defined/ 
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trackable engineered nanomaterials in the lung as a portal 
of entry to the systemic circulation and end organs would 
provide insight into the environmental health effects of air 
pollution and design of inhaled drug delivery systems.
Distal airspaces of the lung are lined with two types of 
alveolar epithelial cells, ie, type I (ATI) and type II (ATII) 
pneumocytes. ATI cells have thin cytoplasmic extensions 
(,1 µm) that cover 90% of the internal surface area of 
the normal human lung and play an important role in gas 
exchange and alveolar fluid balance.5 ATII cells are involved 
in synthesis, secretion, and recycling of surfactant compo-
nents and can transdifferentiate into ATI cells.6–8 However, 
due to the complex anatomy of the lung, specific mechanistic 
information regarding nanoparticle interactions with the 
lung is difficult to obtain from in vivo models. As an alter-
native approach, primary cultured rat ATII cells are known 
to undergo morphologic7 and phenotypic9 transition into 
ATI cell-like monolayers that can serve as a suitable in vitro 
model of the alveolar epithelial barrier for mechanistic 
investigations of transport and cell biology. Such rat alveolar 
epithelial cell monolayers (RAECM) exhibit relatively high 
transmonolayer resistance of about 2.5 kΩ ⋅ cm2 and well 
formed tight junctions, consistent with the expected proper-
ties of alveolar epithelium in vivo.
Semiconductor nanocrystals (eg, quantum dots) have 
improved optical properties compared with other fluoro-
chromes and are used for biological imaging (both in vitro 
and in vivo)10,11 and therapeutic applications (eg, drug deliv-
ery vectors12,13 and photosensitizers for phototherapy14,15). 
  However, the core material of quantum dots (eg, cadmium) 
is toxic to cells and organisms, raising concerns regarding 
their suitability as biomarkers/labels.16,17 In addition, water 
dispersability, biocompatibility, chemical stability, and robust 
optical properties are required for the biological applications 
of quantum dots.18 Chemical coatings and/or surface layering 
are essential for meeting these requirements. These surface 
layers can prevent chemical degradation and/or leaching of 
toxic core materials, improving quantum dot cytocompat-
ibility, and reducing their nonspecific binding.19 Numerous 
modifications of quantum dot surface chemistry have been 
explored, including functionalizable inorganic shells, such 
as silica20,21 or organic layer attachment, eg, polyethylene 
glycol (PEG)22 or bovine serum albumin.23 A surface modi-
fication using PEG is known to reduce cytotoxicity, and the 
amphiphilic properties of PEG result in enhanced solubility. 
Moreover, PEG modifications, ie, PEGylations, are well 
known to be biocompatible and nonimmunogenic, affording 
a long blood circulation time after intravenous injection by 
reducing opsonization via proteins and impeding uptake by 
macrophages in the reticuloendothelial system.24–29
It is currently thought that both the size and surface 
properties of nanoparticles affect the cytotoxicity and 
intracellular fate(s) of nanoparticles.30–33 In this regard, we 
recently reported the trafficking properties of polystyrene 
nanoparticles with variable sizes and surface charges across 
RAECM.30,31 In brief, trafficking rates of polystyrene nano-
particles across RAECM are dependent on both surface 
charge density and size, in that we found an approximately 
20–40 times greater flux for positively (versus negatively) 
charged polystyrene nanoparticles of similar size and that 
larger polystyrene nanoparticles (about 100 nm) cross 
RAECM about 3–4 times slower than smaller polystyrene 
nanoparticles (20 nm) of similar surface charge.31 Polystyrene 
nanoparticles appear to be translocated across RAECM via 
nonendocytic transcellular pathways, possibly involving dif-
fusion across the lipid bilayer of cell plasma membranes.30
In this study, we used PEGylated quantum dots with 
three surface modifications (amine-, carboxylate-, and non-
modified) with which to characterize nanoparticle uptake/
trafficking into/across RAECM. We found that these quan-
tum dots do not affect the barrier properties of   alveolar 
epithelium. They translocate across RAECM via both 
transcellular pathways (which appear to be independent of 
caveolin-, clathrin-, or dynamin-mediated endocytosis) and 
paracellular routes.
Materials and methods
RAECM
The detailed procedure for preparation of RAECM has 
been described previously.34,35 This method involving the 
use of rats has been approved by the Institutional Animal 
Care and Use Committee of the University of Southern 
California. Briefly, ATII cells were freshly isolated from 
adult male, specific pathogen-free, Sprague-Dawley rats 
(125–150 g) using elastase digestion and enriched by 
IgG panning.34,35 Enriched ATII cells were plated onto 
tissue culture-treated polycarbonate filters (Transwell, 
12 mm diameter, 0.4 µm diameter pores, Corning-Costar, 
  Cambridge, MA) at 1.2 × 106 cells/cm2. ATII cells were 
cultured in MDS   (minimal defined serum-free medium with 
10% newborn bovine serum from Omega, Tarzana, CA). 
Minimal defined serum-free medium consists of a 1:1   mixture 
of Dulbecco’s modified Eagle’s medium and Ham’s 
F-12 medium (Sigma, St Louis, MO) supplemented with 
1 mM nonessential amino acids (Sigma), 100 U/mL primocin 
(InvivoGen, San Diego, CA), 10 mM N-(2-hydroxyethyl)
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piperazine-N′-(2-ethanesulfonic acid) (Sigma), 1.25 mg/mL 
bovine serum albumin (BD Bioscience, San Jose, CA), and 
2 mM L-glutamine (Sigma). Cells were maintained at 37°C 
in a humidified atmosphere of 5% CO2 and 95% air and fed 
every other day starting on day 3 in culture when confluent 
monolayers were formed. Transmonolayer resistance and 
potential difference were screened using a Millicell-ERS 
device (Millipore, Bedford, MA). The equivalent active ion 
transport rate was calculated as potential difference/trans-
monolayer resistance. We utilized RAECM at 4–7 days in 
culture with transmonolayer resistance .2.5 kΩ ⋅ cm2 and a 
potential difference .10 mV .
Nanoparticles
PEGylated quantum dots (CdSe/ZnS, core size 5.3 nm, 
hydrodynamic size 25 nm) which were non-modified, 
amine-modified, or carboxylate-modified, were purchased 
from eBioscience (San Diego, CA). Excitation/emission 
wavelengths were 360/610 nm for all quantum dots studied. 
Quantum dot zeta potential in water was determined using a 
Zetasizer (Malvern, Worcestershire, UK) with a measurement 
cell (with built-in electrodes) filled with 1 mL of various 
quantum dots suspended in water at 6.25 µg/mL by applying 
an electric field across the two electrodes.
Quantum dot flux
To measure rates of quantum dot translocation across 
RAECM, apical fluid was replaced at t = 0 with fresh culture 
medium containing various quantum dots at 6.25 µg/mL. 
Apical-to-basolateral flux of quantum dots was estimated 
from quantum dots appearing in the basolateral fluid for 
up to 24 hours at 37°C. Quantum dot concentrations in 
downstream fluid were estimated spectrofluorometrically 
using SpectraMax M2 (Molecular Devices, Sunnyvale, CA). 
Apical [quantum dot] was determined at t = 0 and at the 
end of flux experiments. [Quantum dot] of various samples 
was calculated using a standard curve generated with 
known concentrations of quantum dots in MDS. Flux (J ) 
was calculated as J = (CV)/S/∆t, where C is [quantum dot] 
in basolateral fluid at time t = ∆t, V is basolateral fluid vol-
ume (1.5 mL), S is nominal surface area of the monolayer 
(1.13 cm2) and ∆t is length of time for flux measurement 
(6 or 24 hours).
Effects of decreased transmonolayer 
resistance
In order to determine the effects of “leakier” tight junctions 
(increased tight junctional conductance) on   trafficking 
rates of quantum dots across RAECM, quantum dot 
flux was measured in the presence of 2 mM ethylene 
  glycol-bis(β-aminoethyl ether) N,N,N′,N′-tetra-acetate 
(EGTA, Sigma) in both apical and basolateral fluids. RAECM 
were pretreated with EGTA for 30 minutes, followed by 
apical instillation of carboxylate-, amine-, or non-modified 
quantum dots at a final concentration of 6.25 µg/mL with 
continued presence of 2 mM EGTA in both apical and 
basolateral fluids for 24 hours. Control monolayers were 
exposed apically to various quantum dots (6.25 µg/mL) in 
the absence of EGTA in the apical and basolateral fluids for 
24 hours. Flux of quantum dots was assessed as described 
above. Bioelectric properties (ie, transmonolayer resistance, 
equivalent active ion transport rate, and potential difference) 
of RAECM in the presence and absence of EGTA were 
determined over time.
Effects of decreased temperature
To determine the effects of energy depletion, the flux of 
amine-, carboxylate-, or non-modified quantum dots across 
RAECM was measured at 4°C (and 37°C) over 6 hours using 
an apical [quantum dot] of 6.25 µg/mL.
Effects of endocytosis inhibitors
To explore if quantum dot translocation across RAECM 
involves endocytotic mechanisms, methyl-β-cyclodextrin, 
chlorpromazine, and dynasore were used to disrupt lipid 
raft-mediated endocytosis,30,32,36,37 clathrin-mediated 
endocytosis,30,38 and dynamin-dependent endocytosis 
(including clathrin-mediated and caveolin-mediated 
endocytosis),30,32,39 respectively. Briefly, RAECM were pre-
treated for 30 minutes with methyl-β-cyclodextrin (200 µM, 
Sigma), chlorpromazine (28 µM, Sigma), or dynasore 
(80 µM, Sigma) in both apical and basolateral fluids. RAECM 
were then exposed apically to amine-, carboxylate-, or non-
modified quantum dots (6.25 µg/mL), and the flux of these 
quantum dots was assessed as described above. Endocytosis 
inhibitors were present in both apical and basolateral fluids 
throughout the duration of the flux experiments. Control 
monolayers were exposed apically to amine-, carboxylate-, 
or non-modified quantum dots (6.25 µg/mL) without these 
inhibitors. To determine if dynasore inhibits dynamin-
dependent endocytosis, flux of fluorescein isothiocyanate-
cholera toxin subunit B (50 µg/mL, Sigma), which involves 
caveolae-mediated endocytosis,30 or Alexa 594-transferrin 
(500 µg/mL, Invitrogen), which involves clathrin-mediated 
endocytosis,30 was measured in the presence and absence 
of dynasore. Bioelectric properties (ie, transmonolayer 
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resistance, equivalent active ion transport rate, and potential 
  difference) of RAECM in the presence and absence of 
  inhibitors were determined over time.
Immunofluorescence and confocal  
laser scanning microscopy
RAECM were exposed apically to 6.25 µg/mL amine-, 
carboxylate-, or non-modified quantum dots at 37°C for 
24 hours. RAECM were then washed three times with 
  ice-cold, phosphate-buffered saline (pH 7.2) and fixed with 
ethanol at −20°C for 5 minutes. Fixed RAECM were incu-
bated with phosphate-buffered saline containing both 5% 
bovine serum albumin and 0.2% TX-100 for 1 hour at room 
temperature. Rabbit antibody against zonula occludens-1 
(Zymed Laboratories, San Francisco, CA), diluted (1:100) 
in phosphate-buffered saline containing 1% bovine serum 
albumin was then incubated with RAECM for 1 hour at 
37°C. Goat antirabbit antibody conjugated with Alexa 488 
(Invitrogen) was diluted to 1:100 using 1% bovine serum 
albumin in phosphate-buffered saline and used to incubate 
RAECM at 37°C for 1 hour. These RAECM were rinsed with 
phosphate-buffered saline and mounted on microscope slides 
with mounting medium containing the nuclear staining dye 
4′,6-diamidino-2-phenylindole (DAPI) (Vector,   Burlingame, 
CA). RAECM not exposed to quantum dots or those incu-
bated with primary or secondary antibody alone served as 
negative controls and were similarly   processed. Images were 
acquired with a Leica TCS SP5 confocal fluorescence imag-
ing system (Leica Microsystems, Heidelberg, Germany). The 
SP5 system was built around a Leica DM6000 CS inverted 
microscope which is powered by a wideband, fully automated, 
infrared (680–1080 nm) combined photo-diode pump laser 
and mode-locked titanium:sapphire laser   (Cameleon Ultra II, 
Coherent, Santa Clara, CA) for multiphoton excitation, and/or 
by HeNe and Ar lasers for conventional one photon-excitation 
confocal microscopy. Alexa 488 and DAPI were excited at 
488 and 740 nm, with emission observed at 500–535 nm and 
400–460 nm, respectively.
Statistical analysis
Data are presented as the mean ± standard error of the mean 
(n = total number of RAECM utilized). Student’s t-tests were 
performed for comparisons of two group means.   One-way 
analysis of variance followed by post hoc tests based on 
modified Newman–Keuls procedures was performed to deter-
mine statistical significance among means of at least three 
groups. P , 0.05 was considered to be statistically significant. 
Statistical analyses were carried out using Sigmaplot software 
(San Jose, CA).
Results
A summary of zeta potentials of quantum dots utilized in 
this study measured in water is shown in Table 1. Although 
the PEG surface of quantum dots are amine-, carboxylate-, 
or non-modified, all quantum dots exhibited negative zeta 
potentials, ranging from −15 mV for amine-modified quan-
tum dots to −31 mV for non-modified quantum dots.
Figure 1 shows trafficking rates of amine-, carboxylate-, 
and non-modified quantum dots across RAECM when 
assessed after 24 hours of exposure at an apical [quantum 
dot] of 6.25 µg/mL. Trafficking rates of these quantum 
dots do not appear to be affected by surface charge den-
sity within the range studied herein. Bioelectric properties 
(ie, transmonolayer resistance, equivalent active ion transport 
rate, and potential difference) of RAECM did not change 
significantly in the apical presence of 6.25 µg/mL quantum 
dots for 24 hours (data not shown).
Flux of amine-, carboxylate-, and non-modified quan-
tum dots in the absence of EGTA was 0.013 ± 0.002, 
0.017 ± 0.002, and 0.016 ± 0.004 pg/cm2/second, respec-
tively, and increased by about 50%–130% in the presence 
of 2 mM EGTA (Figure 2). Concomitantly, transmonolayer 
resistance decreased by about 95% in the presence of 2 mM 
EGTA (data not shown). After replacing the bathing media 
with fresh MDS (without EGTA), transmonolayer resistance 
recovered by 75% over 12 hours (data not shown).
Flux of amine-, carboxylate-, and non-modified quan-
tum dots at 37°C was 0.085 ± 0.007, 0.103 ± 0.015, and 
0.111 ± 0.012 pg/cm2/second, respectively, and all increased 
by approximately 85% after 6 hours at 4°C (Figure 3). 
  Transmonolayer resistance after 6 hours at 4°C was about 5% 
of the respective control (data not shown). Transmonolayer 
resistance recovered to approximately 75% of that before 
Table 1 Surface modification and zeta potential of PEGylated 
QD  (composed  of  CdSe/ZnS  with  core  size  of  5.3  nm  and 
hydrodynamic size of 25 nm)
Surface modification Zeta potential (mV) in water 
PEGylated-amine quantum dot  
(PEG-NH2
+-QD)
−15.67 ± 1.46
PEGylated-carboxylate quantum  
dot (PEG-COO−-QD)
−24.47 ± 4.71
PEGylated-non-modified quantum  
dot (PEG-QD)
−31.53 ± 5.78
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reducing temperature to 4°C when temperature was increased 
to 37°C (data not shown).
Figure 4 shows flux of amine-, carboxylate-, and non-
modified quantum dots in the presence or absence of 200 µM 
methyl-β-cyclodextrin. Flux of amine-,   carboxylate-, or 
non-modified quantum dots in the absence of methyl-
β-cyclodextrin was 0.013 ± 0.003, 0.016 ± 0.002, and 
0.012 ± 0.003 pg/cm2/second, respectively, and did not 
decrease in the presence of methyl-β-cyclodextrin compared 
with the respective control. Previously, we showed that flux 
of cholera toxin subunit B (apical concentration 50 µg/mL, 
used as a positive control) across RAECM decreased by about 
75% in the presence of 200 µM methyl-β-cyclodextrin.30 
Transmonolayer resistance of RAECM treated with methyl-
β-cyclodextrin did not change compared with that of the 
control (data not shown).
Flux of amine-, carboxylate-, and non-modified quan-
tum dots at baseline was 0.016 ± 0.002, 0.017 ± 0.001, and 
0.018 ± 0.001 pg/cm2/second, respectively, and did not 
decrease in the presence of 28 µM chlorpromazine compared 
with the respective control (Figure 5). Previously, we showed 
that flux of transferrin (apical concentration 500 µg/mL, used 
as a positive control) decreased by about 85% in the presence 
of chlorpromazine.30 Transmonolayer resistance of RAECM 
treated with chlorpromazine did not change compared with 
that of the control (data not shown).
Figure 6 shows flux of amine-, carboxylate-, and non-
modified quantum dots in the presence or absence of 80 µM 
dynasore. Flux of amine-, carboxylate-, and non-modified 
quantum dots in the absence of dynasore was 0.015 ± 0.002, 
0.022 ± 0.002, and 0.027 ± 0.003 pg/cm2/second, respectively, 
and did not decrease in the presence of dynasore compared 
0.00
PEG-NH2
+-QD
F
l
u
x
 
(
p
g
/
s
/
c
m
2
)
PEG-COO−-QD PEG-QD
0.04
0.08
Figure 1 Fluxes of amine-, carboxylate-, or non-modified quantum dots across rat 
alveolar epithelial cell monolayers over 24 hours are not significantly different from 
each other.
Note: Apical [quantum dot] = 6.25 µg/mL (n = 9).
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Figure 2 Fluxes of quantum dots across rat alveolar epithelial cell monolayers 
treated with 2 mM EGTA for 24 hours increased significantly (by about 50%–130%) 
from respective controls. Transmonolayer resistance of rat alveolar epithelial cell 
monolayers decreased by about 95% during experiments in the presence of EGTA.
Notes: Apical [quantum] = 6.25 µg/mL. *Significantly increased compared with 
control (n = 6).
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Figure 3 Fluxes of quantum dots across rat alveolar epithelial cell monolayers 
increased  significantly  (by  about  85%)  when  temperature  decreased  from 
37°C to 4°C. Transmonolayer resistance of rat alveolar epithelial cell monolayers 
decreased by about 95% at 4°C.
Notes: Apical [quantum dot] = 6.25 µg/mL. *Significantly increased from control 
(n = 9).
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Figure  4  Fluxes  of  quantum  dots  (6.25  µg/mL  apical  concentration)  did  not 
decrease significantly when rat alveolar epithelial cell monolayers were treated 
with 200 µm methyl-β-cyclodextrin for 24 hours. Transmonolayer resistance was 
not significantly affected by the presence of methyl-β-cyclodextrin compared with 
control (n = 6).
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with the respective control. Flux of cholera toxin subunit B and 
transferrin (apical concentrations 50 µg/mL and 500 µg/mL, 
respectively, used as positive controls) in the absence of dyna-
sore was 3.22 ± 0.12 and 29.54 ± 7.32 pg/cm2/second, respec-
tively, and decreased by about 85% and 72%, respectively, 
in the presence of dynasore after 24 hours (data not shown). 
Transmonolayer resistance of RAECM treated with dynasore 
increased by approximately 30% (data not shown).
Confocal photomicrographs (Z-max) of RAECM after 
apical exposure to 6.25 µg/mL amine-modified quantum 
dots for 24 hours are shown in Figure 7. Quantum dots are 
seen predominantly in the cytosol, with no apparent localiza-
tion at cell–cell borders (ie, paracellular pathways). Similar 
observations were noted with carboxylate- and non-modified 
quantum dots (data not shown).
Discussion
This study demonstrates that apical exposure of RAECM 
to PEGylated quantum dots with amine-, carboxylate-, or 
non-modified surfaces for 24 hours does not affect alveolar 
epithelial barrier properties. Quantum dot translocation 
across RAECM via transcellular pathways does not appear to 
require caveolin-, clathrin-, or dynamin-dependent pathways, 
although quantum dot traffic via paracellular pathways may 
account (at least in part) for the observed fluxes.
We have previously reported that cationic polystyrene 
nanoparticles (amidine-modified, zeta potential about 
71 mV) translocate across RAECM 20–40 times faster 
than anionic polystyrene nanoparticles (carboxylate-
modified, zeta potential of about −45 mV).30,31 Although 
the range of surface charge of the amine-, carboxylate-, 
and non-modified PEGylated quantum dots was much less, 
no effect of surface charge on quantum dot flux across 
RAECM was seen.
No detectable translocation of quantum dots with non-
modified, amine-modified, or carboxylate-modified surfaces 
([apical quantum dot] = 25 nM) across RAECM over 24 hours 
was reported by Geys et al,40 while significant increases in 
transmonolayer resistance were observed. The quantum 
dots used by Geys et al40 were not PEGylated, although their 
hydrodynamic size and surface charge were similar to our 
quantum dots. The major difference between the studies is 
that measurable fluxes were noted for PEGylated quantum 
dots (our study) versus none for non-PEGylated quantum 
dots,40 likely due to differences in interactions between 
RAECM and differently coated quantum dots. Greater inter-
nalization of carboxylate-coated quantum dots compared 
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Figure  5  Fluxes  of  quantum  dots  (6.25  µg/mL  apical  concentration)  did  not 
decrease in the presence of 28 µM chlorpromazine for 24 hours. Transmonolayer 
resistance of rat alveolar epithelial cell monolayers after 24 hours of exposure to 
chlorpromazine was not different from control (n = 6).
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Figure 6 Fluxes of quantum dots (6.25 µg/mL apical concentration) did not decrease 
in the presence of 80 µM dynasore for 24 hours. Transmonolayer resistance of rat 
alveolar epithelial cell monolayers was increased by about 30% after 24 hours of 
exposure to dynasore compared with control.
Note: *Significantly increased from control (n = 6).
Figure 7 Confocal photomicrograph showing amine-modified PEGylated quantum 
dots (red) internalized into alveolar epithelial cells following 24 hours of apical 
exposure to 6.25 µg/mL quantum dots. Zonula occludens-1 is shown in green and 
nuclei are shown in blue.
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with that of PEG-coated or PEG-amine-coated quantum dots 
has been reported for human epidermal keratinocytes.41
Although treatment of epithelial cells with EGTA 
(a calcium chelator) increases paracellular permeability to 
small solutes,42–45 it is unknown if nanoparticles traverse 
normal and/or EGTA-disrupted tight junctions. In this study, 
trafficking rates across RAECM of all three quantum dots 
with different surface modifications increased in the pres-
ence of 2 mM EGTA, indicating that these quantum dots 
traverse RAECM via tight junctional pathways following 
EGTA treatment. In contrast, Yacobi et al30 concluded that 
translocation of amidinated (20 and 120 nm) or carboxylated 
(20 and 100 nm) polystyrene nanoparticles across RAECM 
does not take place via paracellular pathways. Trafficking 
of small hydrophilic solutes (up to 10 nm) across epithelial 
barriers can occur via paracellular pathways,46,47 consistent 
with the small core size of the quantum dots utilized in this 
study (about 5 nm).
Quantum dot trafficking increased across RAECM 
when temperature was lowered from 37°C to 4°C. At lower 
temperature, energy-dependent mechanism(s) that may be 
involved in translocation of quantum dots transcellularly 
across RAECM will decrease or stop. However, when tem-
perature was decreased to 4°C, transmonolayer resistance of 
RAECM decreased by about 90%, suggesting that trafficking 
of quantum dots is taking place primarily via paracellular 
pathways at low temperature.
Glycolipid rafts are detergent-insoluble, low-density mem-
brane fractions that are rich in cholesterol and   sphingolipids.48 
Methyl-β-cyclodextrin extracts cholesterol from plasma 
membranes and thereby inhibits lipid raft-  mediated endocy-
tosis (including caveolin-mediated   endocytosis, CLIC/GEEC 
endocytosis, arf 6-mediated endocytosis, flotillin-mediated 
endocytosis, and macropinocytosis).37,38 We   previously 
reported that 200 µM methyl-β-cyclodextrin markedly 
decreases flux of cholera toxin subunit B, a positive control 
for lipid raft-mediated transcytosis across RAECM.30 In the 
present study, flux of quantum dots observed in the presence 
of 200 µM methyl-β-cyclodextrin did not decrease, sug-
gesting that translocation of quantum dots across RAECM 
is not taking place via lipid raft-mediated endocytosis. We 
have reported that translocation of polystyrene nanoparticles 
across RAECM and Madin Darby canine kidney type II cell 
monolayers (MDCK-II) was not decreased in the presence 
of 10–200 µM methyl-β-cyclodextrin.30,32
Clathrin is composed of three light and three heavy chains 
that form a triskelion. Assembly of the triskelion leads to 
formation of a net-like basket (clathrin-coated pit) at the 
cell plasma membrane. Involvement of clathrin-mediated 
  endocytosis in uptake/translocation of various nanoparticles 
in cells and tissues, eg, amidine-modified polystyrene nano-
particles in MDCK-II,32 PEGylated D,L-polylactide (PLA) 
(PEG-PLA) nanoparticles into HeLa cells49 and fullerenic 
nanoparticles into rat fibroblasts and rat hepatoma cells,50 
has been reported. Chlorpromazine and other inhibitors of 
  clathrin-mediated endocytosis cause clathrin and AP-2 adap-
tor protein to relocate to multivesicular bodies and as a result 
inhibit clathrin-mediated endocytosis.51 We reported previously 
that transferrin utilizes clathrin-mediated endocytosis across 
RAECM which was inhibited by 28 µm   chlorpromazine.30 
However, treatment of RAECM with 28 µM chlorpromaz-
ine in our current study did not decrease trafficking rates of 
any quantum dots utilized herein. It has been reported that a 
charge-dependent clathrin-mediated mechanism appears to 
be responsible for uptake of positively (but not negatively) 
charged PEG-PLA nanoparticles into HeLa and MDCK-II 
cells.49,52 In this regard, we recently reported that trafficking 
of positively (but not negatively) charged polystyrene nano-
particles across MDCK-II is clathrin-mediated.32
Dynamin, the membrane scission protein, is a large 
GTPase which forms a helical polymer around the neck of 
newly-formed cell plasma membrane invaginations and, upon 
GTP hydrolysis, mediates the fission of the vesicle from the 
plasma membrane. Dynamin is essential for caveolin-coated 
and clathrin-coated vesicle formation and appears to play 
a role in lipid raft-mediated processes as well. Dynasore, 
a small, cell-permeable molecule, reversibly inhibits the 
GTPase activity of dynamin-1 or dynamin-2 at the cell 
plasma membrane and rapidly blocks vehicle formation.53 
Our data showing that trafficking rates of quantum dots 
did not decrease in the presence of 80 µM dynasore across 
RAECM are consistent with the lack of effect of inhibition 
of endocytosis involving clathrin or lipid rafts (including 
caveolin). Increased trafficking of quantum dots could be 
due to upregulation of other translocation pathways (although 
unlikely to include paracellular pathways with increased 
transmonolayer resistance) in the presence of dynasore. We 
reported recently that dynasore has no effect on traffick-
ing rates of polystyrene nanoparticles (20 or 100/120 nm; 
  amidine-modified or carboxylate-modified) across RAECM.30 
On the other hand, 80 µM dynasore inhibited uptake of posi-
tively charged 100 nm polystyrene nanoparticles in HeLa 
cells by two-fold compared with that of negatively charged 
polystyrene nanoparticles of comparable size.54
Phagocytosis is prevalent in macrophages and dendritic 
cells, although it can be induced in most cells by expression 
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of requisite receptors.55 Phagocytosis has also been reported 
for ATI and ATII cells.56 Internalization of large particles and 
microorganisms, typically greater than 0.5 µm, is known to 
occur via phagocytosis,37 but it is unlikely that PEGylated 
quantum dots (core size 5.3 nm, hydrodynamic size 25 nm) 
are significantly phagocytosed.
In summary, we have shown that translocation of amine-, 
carboxylate-, and non-modified PEGylated quantum dots 
across RAECM occurs both transcellularly (not involving 
major endocytic pathways) and paracellularly. Compared 
with trafficking of polystyrene nanoparticles across RAECM 
and MDCK-II, nanoparticle interactions with epithelial bar-
riers appear to be both cell type-specific and dependent on 
nanoparticle physicochemical properties (eg, size, surface 
charge, and composition).
Acknowledgments
This work was supported in part by the Hastings Foundation, 
Whittier Foundation, and research grants (EY011386, 
EY017293, EY016985, ES017034, ES018782, HL038578, 
HL038621, HL062569, and HL089445) from the National 
Institutes of Health. Dr Crandall is Hastings Professor and 
Norris Chair of Medicine. Dr Borok is Edgington Chair in 
Medicine.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Kim YH, Fazlollahi F, Kennedy IM, et al. Alveolar epithelial cell injury 
due to zinc oxide nanoparticle exposure. Am J Respir Crit Care Med. 
2010;182(11):1398–1409.
  2.  Xia T, Zhao Y, Sager T, et al. Decreased dissolution of ZnO by iron 
doping yields nanoparticles with reduced toxicity in the rodent lung 
and zebrafish embryos. ACS Nano. 2011;5(2):1223–1235.
  3.  Wang H, Wang S, Su H, et al. A supramolecular approach for prepa-
ration of size-controlled nanoparticles. Angew Chem Int Ed Engl. 
2009;48(24):4344–4348.
  4.  De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications 
and hazards. Int J Nanomedicine. 2008;3(2):133–149.
  5.  Haefeli-Bleuer B, Weibel ER. Morphometry of the human pulmonary 
acinus. Anat Rec. 1988;220(4):401–414.
  6.  Crandall ED, Matthay MA. Alveolar epithelial transport. Basic sci-
ence to clinical medicine. Am J Respir Crit Care Med. 2001;163(4): 
1021–1029.
  7.  Cheek JM, Evans MJ, Crandall ED. Type I cell-like morphology in tight 
alveolar epithelial monolayers. Exp Cell Res. 1989;184(2):375–387.
  8.  Cheek JM, Kim KJ, Crandall ED. Tight monolayers of rat alveolar 
epithelial cells: bioelectric properties and active sodium transport. 
Am J Physiol. 1989;256(3 Pt 1):C688–C693.
  9.  Danto SI, Zabski SM, Crandall ED. Reactivity of alveolar epithelial 
cells in primary culture with type I cell monoclonal antibodies. Am J 
Respir Cell Mol Biol. 1992;6(3):296–306.
  10.  Schipper ML, Cheng Z, Lee SW, et al. microPET-based biodistribution 
of quantum dots in living mice. J Nucl Med. 2007;48(9):1511–1518.
  11.  Qian J, Yong KT, Roy I, et al. Imaging pancreatic cancer using 
surface-functionalized quantum dots. J Phys Chem B. 2007;111(25): 
6969–6972.
  12.  Walther C, Meyer K, Rennert R, Neundorf I. Quantum dot-carrier 
peptide conjugates suitable for imaging and delivery applications. 
Bioconjug Chem. 2008;19(12):2346–2356.
  13.  Chakravarthy KV, Davidson BA, Helinski JD, et al. Doxorubicin-
  conjugated quantum dots to target alveolar macrophages and 
  inflammation. Nanomedicine. 2011;7(1):88–96.
  14.  Morosini V, Bastogne T, Frochot C, et al. Quantum dot-folic acid 
conjugates as potential photosensitizers in photodynamic therapy of 
cancer. Photochem Photobiol Sci. 2011;10(5):842–851.
  15.  Wang L, Yang W, Read P, Larner J, Sheng K. Tumor cell apoptosis 
induced by nanoparticle conjugate in combination with radiation 
therapy. Nanotechnology. 2010;21(47):475103–475110.
  16.  Bottrill M, Green M. Some aspects of quantum dot toxicity. Chem 
Commun (Camb). 2011;47(25):7039–7050.
  17.  Geys J, Nemmar A, Verbeken E, et al. Acute toxicity and prothrombotic 
effects of quantum dots: impact of surface charge. Environ Health 
Perspect. 2008;116(12):1607–1613.
  18.  Ghasemi Y, Peymani P, Afifi S. Quantum dot: magic nanopar-
ticle for imaging, detection and targeting. Acta Biomed. 2009;80(2): 
156–165.
  19.  Daou TJ, Li L, Reiss P, Josserand V , Texier I. Effect of poly(ethylene 
glycol) length on the in vivo behavior of coated quantum dots. 
  Langmuir. 2009;25(5):3040–3044.
  20.  Erogbogbo F, Yong KT, Hu R, et al. Biocompatible magnetofluorescent 
probes: luminescent silicon quantum dots coupled with superparamag-
netic iron(III) oxide. ACS Nano. 2010;4(9):5131–5138.
  21.  Ma N, Marshall AF, Gambhir SS, Rao J. Facile synthesis,   silanization, 
and biodistribution of biocompatible quantum dots. Small. 2010;6(14): 
1520–1528.
  22.  Mohs AM, Duan H, Kairdolf BA, Smith AM, Nie S. Proton-resistant 
quantum dots: stability in gastrointestinal fluids and implications for 
oral delivery of nanoparticle agents. Nano Res. 2009;2(6):500–508.
  23.  Chu M, Wu F, Zhang Q, et al. A novel method for preparing quan-
tum dot nanospheres with narrow size distribution. Nanoscale. 
2010;2(4):542–547.
  24.  Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin 
Drug Deliv. 2009;6(1):1–16.
  25.  Laia WC, Liau WB. Thermo-oxidative degradation of poly(ethylene 
glycol)/poly(L-lactic acid) blends. Polymer. 2003;44:8103–8109.
  26.  Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influenc-
ing the stealthiness of colloidal drug delivery systems. Biomaterials. 
2006;27(24):4356–4373.
  27.  Kah JC, Wong KY, Neoh KG, et al. Critical parameters in the pegylation 
of gold nanoshells for biomedical applications: an in vitro macrophage 
study. J Drug Target. 2009;17(3):181–193.
  28.  Niidome T, Yamagata M, Okamoto Y, et al. PEG-modified gold nano-
rods with a stealth character for in vivo applications. J Control Release. 
2006;114(3):343–347.
  29.  Schipper ML, Iyer G, Koh AL, et al. Particle size, surface coating, and 
PEGylation influence the biodistribution of quantum dots in living mice. 
Small. 2009;5(1):126–134.
  30.  Yacobi NR, Malmstadt N, Fazlollahi F, et al. Mechanisms of alveolar 
epithelial translocation of a defined population of nanoparticles. Am J 
Respir Cell Mol Biol. 2010;42(5):604–614.
  31.  Yacobi NR, Demaio L, Xie J, et al. Polystyrene nanoparticle trafficking 
across alveolar epithelium. Nanomedicine. 2008;4(2):139–145.
  32.  Fazlollahi F, Angelow S, Yacobi NR, et al. Polystyrene nanoparticle 
trafficking across MDCK-II. Nanomedicine. 2011;7(5):588–594.
  33.  Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML. Effects of 
nanomaterial physicochemical properties on in vivo toxicity. Adv Drug 
Deliv Rev. 2009;61(6):457–466.
  34.  Borok Z, Danto SI, Zabski SM, Crandall ED. Defined medium for 
primary culture de novo of adult rat alveolar epithelial cells. In Vitro 
Cell Dev Biol Anim. 1994;30A(2):99–104.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2856
Fazlollahi et alInternational Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2011:6
  35.  Borok Z, Hami A, Danto SI, Zabski SM, Crandall ED. Rat serum inhibits 
progression of alveolar epithelial cells toward the type I cell phenotype 
in vitro. Am J Respir Cell Mol Biol. 1995;12(1):50–55.
  36.  Parton RG, Richards AA. Lipid rafts and caveolae as portals for 
  endocytosis: new insights and common mechanisms. Traffic. 2003; 
4(11):724–738.
  37.  Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev 
Biochem. 2009;78:857–902.
  38.  Ivanov AI. Pharmacological inhibition of endocytic pathways: is it 
specific enough to be useful? Methods Mol Biol. 2008;440:15–33.
  39.  Kirchhausen T, Macia E, Pelish HE. Use of dynasore, the small mol-
ecule inhibitor of dynamin, in the regulation of endocytosis. Methods 
Enzymol. 2008;438:77–93.
  40.  Geys J, De Vos R, Nemery B, Hoet PH. In vitro translocation of quan-
tum dots and influence of oxidative stress. Am J Physiol Lung Cell Mol 
Physiol. 2009;297(5):L903–L911.
  41.  Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nano-
particle cellular uptake. Toxicol Sci. 2009;110(1):138–155.
  42.  Collares-Buzato CB, McEwan GT, Jepson MA, Simmons NL, Hirst BH. 
Paracellular barrier and junctional protein distribution depend on baso-
lateral extracellular Ca2+ in cultured epithelia. Biochim Biophys Acta. 
1994;1222(2):147–158.
  43.  Mounier J, Vasselon T, Hellio R, Lesourd M, Sansonetti PJ. Shigella 
flexneri enters human colonic Caco-2 epithelial cells through the baso-
lateral pole. Infect Immun. 1992;60(1):237–248.
  44.  Knipp GT, Ho NF, Barsuhn CL, Borchardt RT. Paracellular diffusion 
in Caco-2 cell monolayers: effect of perturbation on the transport of 
hydrophilic compounds that vary in charge and size. J Pharm Sci. 
1997;86(10):1105–1110.
  45.  Sergent T, Parys M, Garsou S, Pussemier L, Schneider YJ, Larondelle Y. 
Deoxynivalenol transport across human intestinal Caco-2 cells and its 
effects on cellular metabolism at realistic intestinal concentrations. 
Toxicol Lett. 2006;164(2):167–176.
  46.  Kim KJ, Crandall ED. Heteropore populations of bullfrog alveolar 
epithelium. J Appl Physiol. 1983;54(1):140–146.
  47.  Matsukawa Y, Lee VH, Crandall ED, Kim KJ. Size-dependent dextran 
transport across rat alveolar epithelial cell monolayers. J Pharm Sci. 
1997;86(3):305–309.
  48.  Nabi IR, Le PU. Caveolae/raft-dependent endocytosis. J Cell Biol. 
2003;161(4):673–677.
  49.  Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. Targeting of 
nanoparticles to the clathrin-mediated endocytic pathway. Biochem 
Biophys Res Commun. 2007;353(1):26–32.
  50.  Li W CC, Ye C, Wei T, et al. The translocation of fullerenic nanopar-
ticles into lysosome via the pathway of clathrin-mediated endocytosis. 
Nanotechnology. 2008;19(14):145102–145114.
  51.  Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lat-
tices on endosomes reveals a regulatory switch for coated pit formation. 
J Cell Biol. 1993;123(5):1107–1117.
  52.  Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface 
charge of nanoparticles determines their endocytic and transcytotic 
pathway in polarized MDCK cells. Biomacromolecules. 2008;9(2): 
435–443.
  53.  Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. 
Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006;10(6): 
839–850.
  54.  Dausend J, Musyanovych A, Dass M, et al. Uptake mechanism of 
oppositely charged fluorescent nanoparticles in HeLa cells. Macromol 
Biosci. 2008;8(12):1135–1143.
  55.  Qualmann B, Mellor H. Regulation of endocytic traffic by Rho GTPases. 
Biochem J. 2003;371(Pt 2):233–241.
  56.  Corrin B. Phagocytic potential of pulmonary alveolar epithelium with 
particular reference to surfactant metabolism. Thorax. 1970;25(1): 
110–115.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2857
Nanocrystal trafficking across alveolar epithelium